Bullish trading in CGRW sends the stock north. Since October the stock is up 420% and is expected to continue its climb.
An opportunity exists with a small Australian biotech that reminds me a lot of Jazz seven years ago. CLVLY...Clinuvel Pharma. They were just approved for European distribution of their drug Scenesse. The future is potentially explosive. Good luck.
yes, I've been in and out several times in the last few weeks, I'm looking for news/comments as well..seemed to have good support ~170, then when it took off over 180 I thought we were off to the races! Now it's broken down not only past it's 170 support but through it's 50 day M/A as well...any insight as to why would be appreciated! Holding March 210 calls at present, if it doesn't bounce strongly in the next couple of weeks, I may have to bail on that position.
The market looks ready for a pullback but this 5 cent high tech stock is just getting started! Pull up DALT and start your research now because this stock could double within a few days at this pace.
Millennium Healthcare (MHCC) just reported $6.3 million, a 1,200%+ increase in quarter revenues in its recent 10Q filing.
Because Millennium’s diagnostics are preventive, FDA approved, reimbursable and cost patients little to nothing, and because they add significant income for physicians, sales are beginning to increase exponentially. Projected growth is remarkable.
And Millennium’s gross margins are exceptionally high as the equipment and associated costs can pay for themselves in the first 30 days of installation.
Millennium’s network of 1,300 physician offices is growing dramatically and sales and earnings are in the early part of a steep growth curve. There are over 30,000 primary care offices and most of them are going to want MHCC exclusive diagnostics.
$6.3 million was achieved with only a small number of Millennium’s the current 1,300 physician offices.
Millennium has the potential to sign a large number of the 30,000 plus offices.
At 30-50 cents Millennium shares are a ground floor opportunity.
Shares are oversold and exceptionally cheap because the company has paid millions in fees (reported in 10Q) to consultants with shares of stock that they have been selling heavily to convert to cash. This heavy selling has depressed shares prices to a very attractive entry point.
Invest a few minutes of your time to read the 10Q for yourself and confirm an exceptional buying opportunity.
Recommend taking advantage of current tax selling low price and putting into your portfolio now.
MHCC 12 month target - $6.00
Sentiment: Strong Buy
Just like I told you "Papita".........PATIENCE.........will payoff....with...JAZZ$$$$$........good luck....and a GREAT weekend to you.
Sentiment: Strong Buy
Not only have you never seen Xyrem on the shelf, but you've probably never seen what the firm's 10-K says. Do some reading.
Xyrem is sold only thru specialty pharmacies. Like the blockbuster MS drug Tysabri most RPHs will never ever see a rx for Xyrem unless they happen to work at one of the few pharmacies allowed to dispense it. Xyrem's sales have been climbing and presently are running at a $800 million rate.